HSA-/PLGA-nanoparticles as diagnostic markers for hepatocellular carcinoma (HCC)

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. For curative treatment options, early diagnosis is crucial. In this context, the present invention provides a new contrast agent, made of Gd-DTPA-loaded HSA-/PLGA-nanoparticles for magnetic resonance imaging (MRI) enabling the detection of small HCC which are undetectable with current methods and improving differentiation between HCC and benign lesions in the cirrhotic lever.

Further Information: PDF

INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Phone: +49 (0)69/2561632-0

Contact
Dr. Otmar Schöller

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Memory Self-Test via Smartphone

… Can Identify Early Signs of Alzheimer’s disease. Dedicated memory tests on smartphones enable the detection of “mild cognitive impairment”, a condition that may indicate Alzheimer’s disease, with high accuracy….

The Sound of the Perfect Coating

Fraunhofer IWS Transfers Laser-based Sound Analysis of Surfaces into Industrial Practice with “LAwave”. Sound waves can reveal surface properties. Parameters such as surface or coating quality of components can be…

Customized silicon chips

…from Saxony for material characterization of printed electronics. How efficient are new materials? Does changing the properties lead to better conductivity? The Fraunhofer Institute for Photonic Microsystems IPMS develops and…

Partners & Sponsors